Steven Le Gouill, MD, PhD, of Nantes University Hospital and INSERM, discusses in French study findings from the Lysa/Goelams Group on rituximab maintenance after autologous stem cell transplantation in younger patients with mantle cell lymphoma (Abstract 145).
Steven Le Gouill, MD, PhD, of Nantes University Hospital and INSERM, discusses study findings from the Lysa/Goelams Group on rituximab maintenance after autologous stem cell transplantation in younger patients with mantle cell lymphoma (Abstract 145).
Martin Schrappe, MD, of Christian-Albrechts University Kiel, discusses study findings on reduced intensity delayed intensification in standard-risk patients defined by minimal residual disease in childhood acute lymphoblastic leukemia (Abstract 4).
Umberto Vitolo, MD, of Città della Salute e della Scienza Hospital and University, and Sagar Lonial, MD, of Emory University, discuss study findings on obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (Abstract 470).
Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, discusses in French phase III trial findings on lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in the first-line setting (Abstract 471).
Syed A. Abutalib, MD, of Cancer Treatment Centers of America, and Alex F. Herrera, MD, of City of Hope National Medical Center, discuss study findings that suggest allogeneic stem cell transplantation may overcome the chemoresistance of double-hit/double-expressor tumors (Abstract 830).
